TTRX — Turn Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2023016 ·
Last close
$6.05
Market Cap
$180.07M
52W High
$6.75
52W Low
$3.01
ADV30
53,647
Next earnings
2026-05-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Sep 2025 | — | — | — | — | — | — | — |
| Jun 2025 | 0 | — | -1,366,524 | -1,240,415 | 4,331,302 | 3,189,943 | 2,556,806 |
| Mar 2025 | — | — | — | — | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$-20,764,985
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-1,366,524
Pretax Income TTM
$-1,240,415
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | — | — | — |
| Dec 2024 | 0 | -1,797,124 | -1,768,415 | 2,048,889 | 2,226,321 | — | -1,361,305 |
| Dec 2023 | 0 | -2,308,149 | -2,292,267 | 2,013,560 | 1,927,792 | — | -1,377,680 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.15
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp. | $180.93M | $11.35 | — |
| EQ | Equillium, Inc. | $177.67M | $2.81 | — |
| GALT | GALECTIN THERAPEUTICS INC | $175.84M | $2.67 | — |
| NBP | NovaBridge Biosciences | $172.32M | $1.49 | — |
| IMUX | IMMUNIC, INC. | $188.79M | $13.86 | — |
News headlines (Yahoo Finance, 1h cache)
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
2026-06-01 12:30 · Yahoo
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
2026-05-27 12:05 · Yahoo
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
2026-05-19 12:01 · Yahoo
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
2026-05-18 12:05 · Yahoo
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-11 20:05 · Yahoo
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
2026-03-31 20:05 · Yahoo
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
2026-03-24 12:00 · Yahoo
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy
2026-03-02 06:08 · Yahoo
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
2026-02-17 13:00 · Yahoo
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
2026-02-09 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.